Capitalize on Comeback Stories in Micro-Cap Biotech StocksCompanies / BioTechJun 17, 2015 – 09:55 PM GMTBy: TLSReportThe list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors […]
An FDA advisory panel voted in favor of approving Regeneron (REGN – Analyst Report) and partner Sanofi’s PCSK9 inhibitor, Praluent. A few deals were also signed over the last few days by companies like Vertex (VRTX – Analyst Report), Celgene (CELG – Analyst Report) and Seattle Genetics (SGEN – Analyst Report).Recap of the Week’s Most Important Stories1. Regeneron and Sanofi […]
Sarepta Therapeutics (NASDAQ:SRPT)After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy — DMD — to restore dystrophin […]
Eleven Biotherapeutics (EBIO – Snapshot Report) suffered a huge setback with its lead pipeline candidate failing in a late-stage study. Meanwhile, companies like bluebird (BLUE – Snapshot Report), Agios (AGIO – Snapshot Report) and Acceleron (XLRN – Snapshot Report) all got encouraging news on the regulatory front. Achillion (ACHN – Snapshot Report) struck a collaboration agreement with Johnson & Johnson […]
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called “Better Know a District,” which highlights one of the 435 U.S. congressional districts and its representative. While I am no Stephen Colbert, I ;am ;brutally inquisitive when it comes to the 5,000-plus listed companies on the U.S. stock exchanges.That’s why I’ve made it […]
Source: Flickr user Mike PoreskyFew sectors offer a greater potential for risk and reward than biotechnology. It’s a sector where many companies are still in the early stages of their drug development process, but if you happen to catch a winner the returns can compound many times over.Unfortunately, the odds are stacked against biotech investors with far more drugs failing […]
It’s been an eventful week on the pipeline front with companies like Biogen (BIIB – Analyst Report), Prothena (PRTA – Snapshot Report) and Vertex (VRTX – Analyst Report) coming out with data. Meanwhile, Gilead (GILD – Analyst Report) was back in the news once again due to its hepatitis C virus (HCV) franchise.Recap of the Week’s Most Important Stories1. Hopes […]
“Our life is March weather, savage and serene in one hour.” — Ralph Waldo Emerson
Substitute “biotechs” for “our life” and you have the investing version of Emerson’s quote. Depending on how binary events go, they can certainly become savage or serene quite quickly.We asked our team of experts for their top biotech picks to watch this month. Read below to […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.’s David Martin has taken his seat in the grandstands, betting on specialty pharma and one day delivery cialis biotech companies based in Canada, where resource stocks have absorbed so much investment capital that […]
